Hirschsprung disease leaves a newborn's gut missing the nerves that move stool. A study published July 2 in The Journal of Neuroscience ↗ names one protein that helps keep those nerves from forming, and a short fragment of that same protein the body appears to use to fight back.
The disease is congenital and rare. The network of nerve cells that lines the intestine and pushes waste along, called the enteric nervous system, is absent from the last stretch of the colon. Without those nerves the bowel cannot contract in sequence, so stool backs up. The standard treatment is surgery to remove the nerveless segment.
The nerves go missing before birth. The cells that build them, called enteric neural crest cells, normally migrate the full length of the gut during fetal development, seeding nerves as they travel. In Hirschsprung disease they stall before reaching the end, and the reason has never been fully clear.
The brake
The authors found a protein called CAP, also known as SORBS1, sitting at abnormally high levels in the affected gut tissue of children with the disease. In lab cells, too much CAP blocked the neural crest cells from colonizing. It works by latching onto a scaffolding protein called flotillin-1, then pulling in a second one, vinculin, part of the machinery the cells use to grip a surface and crawl along it. High CAP gums up that machinery, and the cells stop moving.
That is one half of the finding: a specific brake on the migration, present in excess exactly where the nerves fail to form.
The counterweight
The other half is the interesting one. Reading out the proteins in diseased tissue by mass spectrometry, the team found a short peptide cut from CAP itself, which they named PDCAP. It competes with full-length CAP for the same docking spot on flotillin-1. When PDCAP wins that competition, CAP's grip loosens, the machinery frees up, and the nerve-precursor cells move again.
In the diseased colon, PDCAP was in short supply, measured with an antibody-based test (ELISA). So the picture is not just too much brake. It is too much brake and not enough of the thing that releases it.
The authors tested the idea in two strains of mice bred to mimic Hirschsprung disease, one carrying a CAP mutation and one missing the Ednrb gene, a long-standing model of the disorder. In both, and in both sexes, adding PDCAP pushed the neural crest cells to colonize and let the enteric nervous system develop.
A fragment against its parent
The framing worth keeping is this. PDCAP is a piece of a protein that antagonizes the whole protein it was cut from. A fragment of CAP undoing CAP. The body seems to run this self-check on its own, and the disease looks partly like a failure of the check, not only an excess of the original protein. That is a cleaner mechanism than "a gene is broken," and it hands researchers something concrete to add back rather than only something to knock down.
This is early. The work is in cells and mice, not people, and there is no drug, only a natural peptide and a rationale for turning it into one. But it is a tidy example of the kind of molecule peptide science keeps circling back to: something short, with a defined partner and a defined job, doing precise work that a large protein cannot. Hirschsprung disease is managed today with a scalpel. A peptide that coaxes the missing nerves into place, if it ever reaches patients, would be a different kind of medicine.